Tuesday, May 22, 2018 10:24 AM
Travel          Hotels Hotels         Tours Tours         Car Rental Cars         Events Events         Flights Flights         Cruises Cruises         Events Refer
Business Name, Category, Keywords
City Name or Zip Code ex: Los Angeles, CA

Virtual Pharma: Lowering Costs for Commercial Products

Posted last August 31, 2015, 10:06 am in Health report article

VxP Pharma Services has recently expanded their services to now provide commercial scale process development and manufacture for multiple dosage forms. Commercially available dosage forms include oral solids, sterile liquids, and transdermal patches, as well as many other hard-to-find dosages.

VxP Pharma CEO - Raymond E. Peck says, “Although the majority of our business comes from development programs for small and large molecules and clinical trials, we have had an increasing number of requests for commercial scale production. Because of this demand, VxP Pharma has decided to expand their capacity in this area to provide a greater number of services and increased level of quality to the pharmaceutical and biotech industries.All of the facilities are based in the United States and have been audited and approved by the US-FDA for cGMP qualified formulation development and commercial scale manufacturing, and domestic/internationally recognized shipping services.”

The Commercial Market

One of the biggest challengesfor a customer is keeping fixed costs down while quickly moving potential drugs through development. Funding has become less readily available in recent years, making companies stretch their dollars as long as possible to keep costs down. That has led us to a widespread adoption of the virtual model like VxP Pharma. The major advantages of utilizing the virtual model approach for commercial manufacturing is faster process development to meet the needs of your dosage form, coupled with a lower total cost compared to the industry average.

Faster Process Development for Commercial Upscale

The pressure to keep operations lean and mean have forced many companies to develop quicker turn-around times for drugs reaching proof-of-concept trials. Preclinical studies are a major obstacle when developing drugs early in development and many Big Pharma companies have too many projects at this stage in the pipeline. Utilizing virtual companies at this stage to help with the early development work can save years of time and will free up the team to focus on more important projects.

Lower Costs with Virtual Pharma

Keeping fixed costs down is a major concern when managing a development project from start to finish. That’s led many mid-size and large pharma and biotech companies to focus on the virtual model. For example, the Chorus group, a division of Eli Lilly& Company, recently publicized their approximate costs when utilizing the virtual model for the majority of their development services. Since Chorus’ inception in 2002, the group has moved many of their drugs from preclinical to proof-of-concept trials at 10% of the previous total costs for the programs. Because of such a vast decrease in spending for R&D and production with the virtual model, many companies are choosing the “virtual model” route.



VxP Pharma operates as a full service CRO/CMO offering drug development services, including commercial scale production. VxP is headquartered in Indianapolis, Indiana. To find out more, please visit: www.vxppharma.com or call at 317-759-2299.